Chen Xiao-Ying, Wang Qian-Yun, Yan Zhan-Feng, Wang Yu-Yang, Pan Xing-Ru, Ou Meng-Yuan, Liu Xue-Han, Liu Jian-Ping, Jin Xin-Yan
Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, China.
Integr Med Res. 2025 Mar;14(1):101116. doi: 10.1016/j.imr.2024.101116. Epub 2024 Dec 26.
Allergic rhinitis (AR) is a prevalent allergic condition affecting the nasal mucosa. Intranasal acupuncture therapy (IAT), an innovative therapy that involves the precise insertion of acupuncture needles into specific nasal acupoints, has demonstrated potential effects in managing AR. The aim of this study was to evaluate the effectiveness and safety of IAT in the management of AR.
Nine databases were systematically searched for randomized controlled trials (RCTs) from their inception to September 2024. We included participants who were diagnosed with AR and who received IAT alone or as add-on treatment to conventional treatment. The Cochrane risk of bias 2.0 tool and the GRADE approach were used to assess the quality of the studies. A meta-analysis was performed via RevMan 5.4.1 software.
Twenty-one RCTs with 1889 participants were included. The certainty of evidence was generally low or moderate. Compared with sham acupuncture, the IAT significantly reduced the total nasal symptom score (MD -2.65, 95% CI -4.01 to -1.29, 1 RCT, 30 participants, moderate evidence). Compared to an antihistamine, IAT was associated with a lower total nasal non-symptom score (MD -0.44, 95% CI -0.64 to -0.25, 5 RCTs, 295 participants, moderate evidence) and a better quality of life measured by the rhinoconjunctivitis quality of life questionnaire (MD -13.72, 95% CI -18.01 to -9.43, 4 RCTs, 255 participants, moderate evidence). No serious adverse events were reported.
The IAT may be beneficial for improving AR-related symptoms and quality of life. However, the safety of the IAT remains unclear due to inadequate reporting. Further high-quality, rigorously designed, and well-reported trials are needed.
PROSPERO, CRD42024526357.
变应性鼻炎(AR)是一种影响鼻黏膜的常见变应性疾病。鼻内针刺疗法(IAT)是一种创新疗法,通过将针刺精确刺入特定鼻穴位发挥作用,已显示出在治疗AR方面的潜在效果。本研究旨在评估IAT治疗AR的有效性和安全性。
系统检索9个数据库,纳入从数据库建立至2024年9月的随机对照试验(RCT)。我们纳入了被诊断为AR且单独接受IAT或作为传统治疗附加治疗的参与者。采用Cochrane偏倚风险2.0工具和GRADE方法评估研究质量。通过RevMan 5.4.1软件进行荟萃分析。
纳入21项RCT,共1889名参与者。证据的确定性一般为低或中等。与假针刺相比,IAT显著降低了总鼻症状评分(MD -2.65,95%CI -4.01至-1.29,1项RCT,30名参与者,中等证据)。与抗组胺药相比,IAT与较低的总鼻非症状评分(MD -0.44,95%CI -0.64至-0.25,5项RCT,295名参与者,中等证据)以及通过鼻结膜炎生活质量问卷测量的更好生活质量相关(MD -13.72,95%CI -18.01至-9.43,4项RCT,255名参与者,中等证据)。未报告严重不良事件。
IAT可能有助于改善AR相关症状和生活质量。然而,由于报告不足,IAT的安全性仍不明确。需要进一步开展高质量、设计严谨且报告完善的试验。
PROSPERO,CRD42024526357。